Jennifer Edwards
Primary Care · Princeton, NJNPI 1801472436
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,012 of the $13,634 with a category attached, or 80.8%. It is spread thinly across 30 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $6,525, more than ten times the $573 reported in 2021. Among primary care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 682 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arcutis Biotherapeutics, Inc.$3K
- AbbVie$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Sun Pharmaceutical Industries Inc.$933
- Incyte Corporation$693
- Novartis$620
- plus $5K from 24 others
What the payments were for
- Consulting fees$2,49018%
- Food & beverage$11,01281%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 86 | $2,709 |
| AbbVie | 136 | $2,227 |
| E.r. Squibb & Sons, L.L.C. | 42 | $1,754 |
| Sun Pharmaceutical Industries Inc. | 43 | $933 |
| Incyte Corporation | 38 | $693 |
| Novartis | 34 | $620 |
| Regeneron Healthcare Solutions, Inc. | 24 | $586 |
| Mayne Pharma Commercial LLC | 38 | $485 |
| Dermavant Sciences, Inc. | 35 | $418 |
| Galderma Laboratories, L.p. | 28 | $410 |
| Pfizer | 23 | $380 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 32 | $364 |
| Johnson & Johnson(2 entities) | 16 | $344 |
| Lilly USA, LLC | 26 | $322 |
| Sanofi | 10 | $303 |
| Journey Medical Corporation | 9 | $159 |
| Verrica Pharmaceuticals Inc. | 13 | $148 |
| LEO Pharma Inc. | 8 | $147 |
| Amgen | 8 | $123 |
| Organon | 7 | $92 |
| UCB, Inc. | 5 | $92 |
| Kyowa Kirin, Inc. | 4 | $70 |
| EPI Health, LLC | 4 | $52 |
| Almirall LLC | 3 | $47 |
| Genentech USA, Inc. | 3 | $43 |
| LNHC, Inc | 2 | $37 |
| Botanix SB Inc | 2 | $30 |
| Biofrontera Inc. | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Strata Skin Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,634 in reported general payments places this provider in the 95th percentile of 330 primary care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $81,218 |
| JubliaEfinaconazole | 14 | $20,493 |
| Mupirocin | 363 | $2,456 |
| Clobetasol Propionate | 80 | $1,853 |
| Fluorouracil | 34 | $1,700 |
| Clindamycin Phosphate | 37 | $1,205 |
| Ketoconazole | 66 | $931 |
| Triamcinolone Acetonide | 64 | $882 |
| Mometasone Furoate | 50 | $877 |
| Metronidazole | 17 | $612 |
| Doxycycline Hyclate | 41 | $534 |
| Gentamicin Sulfate | 16 | $529 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 18 | $407 |
| Desonide | 11 | $404 |
| Hydrocortisone | 83 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $364 | $20,49314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 primary care providers in New Jersey.
Other primary care in Princeton
- Michael Zito GovertNeptune$61K
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
- Shazam BacchusNewark$7K
- Anna NievesBasking Ridge$7K
- Kristen BeerFreehold$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.